Dr. Fred Cohen is a Co-Founder and serves as Senior Advisor and Senior Managing Director at Vida Ventures (Boston). He serves as Board Member at Kadiant. He also served as the Advisor at Mission Bay Capital. Prior to Vida, he was a Partner and founder of TPG Biotechnology, a life science-focused investment effort from 2001-to 2016. From 1980 through 2014, he was at UCSF where he held various clinical responsibilities as a research scientist, an internist for hospitalized patients, a consulting endocrinologist, and the Chief of the Division of Endocrinology and Metabolism. His research interests included structure-based drug design, prion diseases, computational biology, and heteropolymer chemistry. He has published over 200 peer-reviewed articles, participated as a co-inventor on over 10 patents, and has served as an editor or editorial board member of several international scientific journals. He received his B.S. degree in Molecular Biophysics and Biochemistry from Yale University, his D.Phil. in Molecular Biophysics from Oxford on a Rhodes Scholarship, his M.D. from Stanford, and his postdoctoral training and postgraduate medical training in Internal Medicine and Endocrinology at UCSF. He is a Fellow of the American College of Physicians and the American College of Medical Informatics and a member of the American Society for Clinical Investigation and Association of American Physicians. He has received several awards for his work including a Searle Scholarship, Young Investigator Awards from the Endocrine Society and the Western Society for Clinical Investigation, and the LVMH Science pour l'art prize (shared with Stanley Prusiner). He was elected to the Institute of Medicine of the National Academy of Sciences in 2004 and the American Academy of Arts and Sciences in 2008. He currently serves on the Board of Directors of several biotechnology and pharmaceutical organizations including CareDx (NASDAQ: CDNA), Progyny (NASDAQ: PGNY), Veracyte (NASDAQ: VCYT), and UroGen (NASDAQ: URGN). He was Co-Founder and Executive Chairman of Cell Design Labs and a former Director of Quintiles (NYSE: Q), Aptalis Pharma, Rapid Micro Biosystems, Roka (NASDAQ: ROKA), Five Prime Therapeutics (NASDAQ: FPRX), Genomic Health (NASDAQ: GHDX) and Tandem Diabetes (NASDAQ: TNDM).
Individual/Angel
